Antiplatelet and anticoagulant therapies in hereditary hemorrhagic telangiectasia: A large French cohort study (RETROPLACOTEL)

It is unclear whether hereditary hemorrhagic telangiectasia (HHT) patients can tolerate antithrombotic therapies (AT) including antiplatelet (AP) and/or anticoagulant (AC) agents.

Source: Thrombosis Research - July 6, 2023 Category: Hematology Authors: Vincent Grobost, Sami Hammi, Bruno Pereira, Alexandre Guilhem, Pierre Duffau, Julie Seguier, Antoine Parrot, Giovanni Gautier, Laurent Alric, Mallorie Kerjouan, Xavier Le Guillou, Delphine Simon, Laurent Chaussavoine, Murielle Rondeau-Lutz, Vanessa Leguy- Tags: Full Length Article Source Type: research